# V Perkovic

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/v-perkovic/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21 |
| Field | Diabetes Treatment and Management |
| h-index | 4 |
| i10-index | 0 |
| Last Known Institution | UNSW Sydney |
| OpenAlex ID | https://openalex.org/A5135098734 |
| Works | 11 |

## Researcher papers

- [Finerenone in Persons with Chronic Kidney Disease without Diabetes](https://scholariq.org/papers/finerenone-in-persons-with-chronic-kidney-disease-without-diabetes/)
- [Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases](https://scholariq.org/papers/finerenone-in-patients-with-chronic-kidney-disease-due-to-glomerular-diseases/)
- [Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)](https://scholariq.org/papers/efficacy-and-safety-of-finerenone-in-patients-with-chronic-kidney-disease-an/)
- [Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial](https://scholariq.org/papers/telitacicept-for-iga-nephropathy-interim-analysis-of-a-phase-3-trial/)
- [Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease](https://scholariq.org/papers/kidney-and-survival-benefits-of-semaglutide-in-diabetes-with-chronic-kidney/)
- [Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial](https://scholariq.org/papers/semaglutide-reduced-risks-of-major-kidney-outcomes-irrespective-of-ckd-severity/)
- [Impact of Semaglutide on Kidney, Cardiovascular, and Mortality Outcomes by Baseline BMI and Weight Loss in People with T2D and CKD—Data from the FLOW Trial](https://scholariq.org/papers/impact-of-semaglutide-on-kidney-cardiovascular-and-mortality-outcomes-by/)
- [Iron deficiency and risk of cardiovascular events in CKD: insights from the ASCEND-ND trial](https://scholariq.org/papers/iron-deficiency-and-risk-of-cardiovascular-events-in-ckd-insights-from-the/)
- [Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial](https://scholariq.org/papers/response-to-comment-on-rossing-et-al-nuances-in-interpretation-assessing-the/)
- [Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial](https://scholariq.org/papers/efficacy-and-safety-of-daprodustat-for-treatment-of-anemia-of-chronic-kidney/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Erythropoietin and Anemia Treatment](https://scholariq.org/topics/erythropoietin-and-anemia-treatment/)

## Researcher university

- [UNSW Sydney](https://scholariq.org/institutions/unsw-sydney/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.